Loading...
•
Mar 31, 2024
Pulmonx Q1 2024 Earnings Report
Pulmonx achieved 30% year-over-year worldwide revenue growth.
Key Takeaways
Pulmonx reported first quarter 2024 financial results, achieving a 30% year-over-year worldwide revenue growth. The company's U.S. revenue increased by 38%, and it realized a gross margin of 75%.
Worldwide revenue reached $18.9 million, a 30% increase year-over-year.
U.S. revenue was $12.9 million, representing a 38% year-over-year growth.
Gross margin was 75% in the first quarter of 2024.
First patient treated with the AeriSeal® System in CONVERT II pivotal clinical trial.
Revenue by Geographic Location
Forward Guidance
Pulmonx continues to expect revenue for the full year 2024 to be in the range of $81 million to $84 million. The Company also continues to expect gross margin for the full year 2024 to fall within the range of 74% to 75%. Pulmonx now expects total operating expenses for the full year 2024 to fall within the range of $127 million to $129 million, inclusive of approximately $25 million of non-cash stock-based compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...